KMB vs STRO · P/E 19, rev $20.06B vs rev $62.0M
Kimberly-Clark Corporation (KMB) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Kimberly-Clark Corporation (KMB) is a household & personal products company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported KMB revenue for 2024-12-31 was $20.06B. Net income was $2.58B. Revenue was down 1.8% from 2023-12-31 to 2024-12-31. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
KMB currently screens at market cap $32.88B and trailing P/E 19.2. STRO currently screens at market cap $470.8M.
Not investment advice. Open the KMB and STRO stock pages for the full models.
Not investment advice.